Loading...

Brilliant Violet 510™ anti-human CD4 Antibody Brilliant Violet 510™ anti-human CD4 Antibody

Pricing & Availability
Clone
OKT4 (See other available formats)
Regulatory Status
RUO
Workshop
HCDM listed
Other Names
T4
Isotype
Mouse IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
OKT4_BV510_CD4_Antibody_FC_082312
Human peripheral lymphocytes were stained with CD3 APC and CD4 (clone OKT4) Brilliant Violet 510™.
  • OKT4_BV510_CD4_Antibody_FC_082312
    Human peripheral lymphocytes were stained with CD3 APC and CD4 (clone OKT4) Brilliant Violet 510™.
Compare all formats See Brilliant Violet 510™ spectral data
Cat # Size Price Quantity Check Availability Save
317443 25 tests DKK1046
Check Availability


Need larger quantities of this item?
Request Bulk Quote
317444 100 tests DKK2323
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4, also known as T4, is a 55 kD single-chain type I transmembrane glycoprotein expressed on most thymocytes, a subset of T cells, and monocytes/macrophages. CD4, a member of the Ig superfamily, recognizes antigens associated with MHC class II molecules and participates in cell-cell interactions, thymic differentiation, and signal transduction. CD4 acts as a primary receptor for HIV, binding to HIV gp120. CD4 has also been shown to interact with IL-16. 

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Cynomolgus, Rhesus
Reported Reactivity
Chimpanzee
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
Human peripheral T cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 510™ under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Brilliant Violet 510™ excites at 405 nm and emits at 510 nm. The bandpass filter 510/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 510™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

The OKT4 antibody binds to the D3 domain of CD4 and does not block HIV binding. Additional reported applications (for the relevant formats) include: immunohistochemistry of frozen sections and blocking of T cell activation. This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 317453 and 317454).

In a small subset of individuals, the OKT4 clone does not bind to CD4 due to polymorphisms in CD4.9

Application References
  1. Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  2. Reinherz EL, et al. 1979. Proc. Natl. Acad. Sci. 76:4061.
  3. Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (FC) PubMed
  4. Cicin-Sain L, et al. 2010. J. Immunol. 184:6739. PubMed
  5. Rosenzweig M, et al. 2001. J. Med. Primatol. 30:36.
  6. Linder J, et al. 1987. Am. J. Pathol. 127:1.
  7. Boche D, et al. 1999. J. Neurovirol. 5:232. (IHC)
  8. Reinherz EL, et al. 1979. Proc. Natl. Acad. Sci. USA. 76:4061. (Immunogen)
  9. Lederman S, et al. 1991. Mol Immunol. 28:1171-81.
Product Citations
  1. Ghassemi S, et al. 2022. Nat Biomed Eng. 6:118. PubMed
  2. Asashima H, et al. 2022. J Clin Invest. 132: . PubMed
  3. Gkika E, et al. 2023. NPJ Precis Oncol. 7:24. PubMed
  4. Tan X, et al. 2023. Adv Sci (Weinh). 10:e2206768. PubMed
  5. Boucher LE, et al. 2023. MAbs. 15:2195517. PubMed
  6. Apte SH, et al. 2020. Clin Transl Immunology. 9:e1209. PubMed
  7. Carre C, et al. 2021. iScience. 24:102970. PubMed
  8. Roberts A, et al. 2021. Sci Rep. 11:4030. PubMed
  9. Wang M, et al. 2022. Immun Inflamm Dis. 10:e626. PubMed
  10. Peng S et al. 2019. Cell Rep. 28(10):2728-2738 . PubMed
  11. Kasper M, et al. 2021. Elife. 10:. PubMed
  12. Wang S, et al. 2021. Exp Ther Med. 21:37. PubMed
  13. Vijayakumar B, et al. 2022. Immunity. . PubMed
  14. Vetsika EK, et al. 2021. Cancers (Basel). 13:. PubMed
  15. Guedan S, et al. 2018. JCI Insight. 3. PubMed
  16. Priyanto H, et al. 2021. J Clin Tuberc Other Mycobact Dis. 22:100214. PubMed
  17. Caduff N, et al. 2021. Cell Reports. 35(5):109056. PubMed
  18. Heger L, et al. 2018. Front Immunol. 9:744. PubMed
  19. Herrera FG, et al. 2019. Int J Radiat Oncol Biol Phys. 103:320. PubMed
  20. Breen EC, et al. 2022. iScience. 25:104488. PubMed
  21. Tu HA, et al. 2020. Cell Rep Med. 1:100155. PubMed
  22. Kalina T, et al. 2020. Front Immunol. 11:371. PubMed
  23. Idorn M, et al. 2018. Oncoimmunology. 7:e1412029. PubMed
  24. Khaitan A, et al. 2016. PLoS One. 11: 0161786. PubMed
  25. Lundtoft C, et al. 2017. PLoS Pathogens. 13(6):e1006425. PubMed
  26. De Domenico E, et al. 2020. STAR Protoc. 1:100233. PubMed
  27. Meckiff BJ, et al. 2020. Cell. 183(5):1340-1353.e16. PubMed
  28. Wing A, et al. 2018. Cancer Immunol Res. 6:605. PubMed
  29. Riese P, et al. 2022. Nat Commun. 13:6894. PubMed
  30. Janssen JJE, et al. 2022. Am J Physiol Endocrinol Metab. 322:E141. PubMed
  31. Menges D, et al. 2022. Nat Commun. 13:4855. PubMed
  32. Willmann K, et al. 2014. Nat Commun. 5:5360. PubMed
  33. Kaiser FMP, et al. 2021. J Allergy Clin Immunol. 147:391. PubMed
  34. Festag J, et al. 2020. Mol Ther Nucleic Acids. 1.330555556. PubMed
  35. Castellarin M, et al. 2020. JCI Insight. 5:00. PubMed
  36. Mackroth M, et al. 2016. PLoS Pathog. 12:e1005909. PubMed
  37. Diamantopoulos PT, et al. 2022. Cancers (Basel). 14:. PubMed
  38. Clayton KL, et al. 2021. Cell Host Microbe. 29(3):435-447.e9. PubMed
  39. Steindor M, et al. 2015. PLoS One. 10:119737. PubMed
  40. Todnem Sakkestad S, et al. 2019. Pathogens. 8. PubMed
  41. Kenswil KJG, et al. 2021. Exp Hematol. S0301-472X:00426. PubMed
  42. van Dongen JJM, et al. 2019. Front Immunol. 10:1271. PubMed
  43. Sananez I, et al. 2021. EBioMedicine. 72:103615. PubMed
  44. Ghassemi S, et al. 2022. Nat Biomed Eng. 6:118. PubMed
  45. Asashima H, et al. 2022. J Clin Invest. 132: . PubMed
  46. Gkika E, et al. 2023. NPJ Precis Oncol. 7:24. PubMed
  47. Tan X, et al. 2023. Adv Sci (Weinh). 10:e2206768. PubMed
  48. Boucher LE, et al. 2023. MAbs. 15:2195517. PubMed
  49. Apte SH, et al. 2020. Clin Transl Immunology. 9:e1209. PubMed
  50. Carre C, et al. 2021. iScience. 24:102970. PubMed
  51. Roberts A, et al. 2021. Sci Rep. 11:4030. PubMed
  52. Wang M, et al. 2022. Immun Inflamm Dis. 10:e626. PubMed
  53. Peng S et al. 2019. Cell Rep. 28(10):2728-2738 . PubMed
  54. Kasper M, et al. 2021. Elife. 10:. PubMed
  55. Wang S, et al. 2021. Exp Ther Med. 21:37. PubMed
  56. Vijayakumar B, et al. 2022. Immunity. . PubMed
  57. Vetsika EK, et al. 2021. Cancers (Basel). 13:. PubMed
  58. Guedan S, et al. 2018. JCI Insight. 3. PubMed
  59. Priyanto H, et al. 2021. J Clin Tuberc Other Mycobact Dis. 22:100214. PubMed
  60. Caduff N, et al. 2021. Cell Reports. 35(5):109056. PubMed
  61. Heger L, et al. 2018. Front Immunol. 9:744. PubMed
  62. Herrera FG, et al. 2019. Int J Radiat Oncol Biol Phys. 103:320. PubMed
  63. Breen EC, et al. 2022. iScience. 25:104488. PubMed
  64. Tu HA, et al. 2020. Cell Rep Med. 1:100155. PubMed
  65. Kalina T, et al. 2020. Front Immunol. 11:371. PubMed
  66. Idorn M, et al. 2018. Oncoimmunology. 7:e1412029. PubMed
  67. Khaitan A, et al. 2016. PLoS One. 11: 0161786. PubMed
  68. Lundtoft C, et al. 2017. PLoS Pathogens. 13(6):e1006425. PubMed
  69. De Domenico E, et al. 2020. STAR Protoc. 1:100233. PubMed
  70. Meckiff BJ, et al. 2020. Cell. 183(5):1340-1353.e16. PubMed
  71. Wing A, et al. 2018. Cancer Immunol Res. 6:605. PubMed
  72. Riese P, et al. 2022. Nat Commun. 13:6894. PubMed
  73. Janssen JJE, et al. 2022. Am J Physiol Endocrinol Metab. 322:E141. PubMed
  74. Menges D, et al. 2022. Nat Commun. 13:4855. PubMed
  75. Willmann K, et al. 2014. Nat Commun. 5:5360. PubMed
  76. Kaiser FMP, et al. 2021. J Allergy Clin Immunol. 147:391. PubMed
  77. Festag J, et al. 2020. Mol Ther Nucleic Acids. 1.330555556. PubMed
  78. Castellarin M, et al. 2020. JCI Insight. 5:00. PubMed
  79. Mackroth M, et al. 2016. PLoS Pathog. 12:e1005909. PubMed
  80. Diamantopoulos PT, et al. 2022. Cancers (Basel). 14:. PubMed
  81. Clayton KL, et al. 2021. Cell Host Microbe. 29(3):435-447.e9. PubMed
  82. Steindor M, et al. 2015. PLoS One. 10:119737. PubMed
  83. Todnem Sakkestad S, et al. 2019. Pathogens. 8. PubMed
  84. Kenswil KJG, et al. 2021. Exp Hematol. S0301-472X:00426. PubMed
  85. van Dongen JJM, et al. 2019. Front Immunol. 10:1271. PubMed
  86. Sananez I, et al. 2021. EBioMedicine. 72:103615. PubMed
RRID
AB_2561377 (BioLegend Cat. No. 317443)
AB_2561866 (BioLegend Cat. No. 317444)

Antigen Details

Structure
Ig superfamily, type I transmembrane glycoprotein, 55 kD
Distribution

T cell subset, majority of thymocytes, monocytes/macrophages

Function
MHC class II co-receptor, lymphocyte adhesion, thymic differentiation, HIV receptor
Ligand/Receptor
MHC class II molecules, HIV gp120, IL-16
Cell Type
Macrophages, Monocytes, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Center D, et al. 1996. Immunol. Today 17:476.
2. Gaubin M, et al. 1996. Eur. J. Clin. Chem. Clin. Biochem. 34:723.

Gene ID
920 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
Go To Top Version: 4    Revision Date: 07/13/2015

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
OKT4 (See other available formats)
Regulatory Status
RUO
Workshop
HCDM listed
Other Names
T4
Isotype
Mouse IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
OKT4_BV510_CD4_Antibody_FC_082312
Human peripheral lymphocytes were stained with CD3 APC and CD4 (clone OKT4) Brilliant Violet 510™.
  • OKT4_BV510_CD4_Antibody_FC_082312
    Human peripheral lymphocytes were stained with CD3 APC and CD4 (clone OKT4) Brilliant Violet 510™.
Compare all formats See Brilliant Violet 510™ spectral data
Cat # Size Price Quantity Check Availability Save
317443 25 tests DKK1046
Check Availability


Need larger quantities of this item?
Request Bulk Quote
317444 100 tests DKK2323
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4, also known as T4, is a 55 kD single-chain type I transmembrane glycoprotein expressed on most thymocytes, a subset of T cells, and monocytes/macrophages. CD4, a member of the Ig superfamily, recognizes antigens associated with MHC class II molecules and participates in cell-cell interactions, thymic differentiation, and signal transduction. CD4 acts as a primary receptor for HIV, binding to HIV gp120. CD4 has also been shown to interact with IL-16. 

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Cynomolgus, Rhesus
Reported Reactivity
Chimpanzee
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
Human peripheral T cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 510™ under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Brilliant Violet 510™ excites at 405 nm and emits at 510 nm. The bandpass filter 510/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 510™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

The OKT4 antibody binds to the D3 domain of CD4 and does not block HIV binding. Additional reported applications (for the relevant formats) include: immunohistochemistry of frozen sections and blocking of T cell activation. This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 317453 and 317454).

In a small subset of individuals, the OKT4 clone does not bind to CD4 due to polymorphisms in CD4.9

Application References
  1. Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  2. Reinherz EL, et al. 1979. Proc. Natl. Acad. Sci. 76:4061.
  3. Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (FC) PubMed
  4. Cicin-Sain L, et al. 2010. J. Immunol. 184:6739. PubMed
  5. Rosenzweig M, et al. 2001. J. Med. Primatol. 30:36.
  6. Linder J, et al. 1987. Am. J. Pathol. 127:1.
  7. Boche D, et al. 1999. J. Neurovirol. 5:232. (IHC)
  8. Reinherz EL, et al. 1979. Proc. Natl. Acad. Sci. USA. 76:4061. (Immunogen)
  9. Lederman S, et al. 1991. Mol Immunol. 28:1171-81.
Product Citations
  1. Ghassemi S, et al. 2022. Nat Biomed Eng. 6:118. PubMed
  2. Asashima H, et al. 2022. J Clin Invest. 132: . PubMed
  3. Gkika E, et al. 2023. NPJ Precis Oncol. 7:24. PubMed
  4. Tan X, et al. 2023. Adv Sci (Weinh). 10:e2206768. PubMed
  5. Boucher LE, et al. 2023. MAbs. 15:2195517. PubMed
  6. Apte SH, et al. 2020. Clin Transl Immunology. 9:e1209. PubMed
  7. Carre C, et al. 2021. iScience. 24:102970. PubMed
  8. Roberts A, et al. 2021. Sci Rep. 11:4030. PubMed
  9. Wang M, et al. 2022. Immun Inflamm Dis. 10:e626. PubMed
  10. Peng S et al. 2019. Cell Rep. 28(10):2728-2738 . PubMed
  11. Kasper M, et al. 2021. Elife. 10:. PubMed
  12. Wang S, et al. 2021. Exp Ther Med. 21:37. PubMed
  13. Vijayakumar B, et al. 2022. Immunity. . PubMed
  14. Vetsika EK, et al. 2021. Cancers (Basel). 13:. PubMed
  15. Guedan S, et al. 2018. JCI Insight. 3. PubMed
  16. Priyanto H, et al. 2021. J Clin Tuberc Other Mycobact Dis. 22:100214. PubMed
  17. Caduff N, et al. 2021. Cell Reports. 35(5):109056. PubMed
  18. Heger L, et al. 2018. Front Immunol. 9:744. PubMed
  19. Herrera FG, et al. 2019. Int J Radiat Oncol Biol Phys. 103:320. PubMed
  20. Breen EC, et al. 2022. iScience. 25:104488. PubMed
  21. Tu HA, et al. 2020. Cell Rep Med. 1:100155. PubMed
  22. Kalina T, et al. 2020. Front Immunol. 11:371. PubMed
  23. Idorn M, et al. 2018. Oncoimmunology. 7:e1412029. PubMed
  24. Khaitan A, et al. 2016. PLoS One. 11: 0161786. PubMed
  25. Lundtoft C, et al. 2017. PLoS Pathogens. 13(6):e1006425. PubMed
  26. De Domenico E, et al. 2020. STAR Protoc. 1:100233. PubMed
  27. Meckiff BJ, et al. 2020. Cell. 183(5):1340-1353.e16. PubMed
  28. Wing A, et al. 2018. Cancer Immunol Res. 6:605. PubMed
  29. Riese P, et al. 2022. Nat Commun. 13:6894. PubMed
  30. Janssen JJE, et al. 2022. Am J Physiol Endocrinol Metab. 322:E141. PubMed
  31. Menges D, et al. 2022. Nat Commun. 13:4855. PubMed
  32. Willmann K, et al. 2014. Nat Commun. 5:5360. PubMed
  33. Kaiser FMP, et al. 2021. J Allergy Clin Immunol. 147:391. PubMed
  34. Festag J, et al. 2020. Mol Ther Nucleic Acids. 1.330555556. PubMed
  35. Castellarin M, et al. 2020. JCI Insight. 5:00. PubMed
  36. Mackroth M, et al. 2016. PLoS Pathog. 12:e1005909. PubMed
  37. Diamantopoulos PT, et al. 2022. Cancers (Basel). 14:. PubMed
  38. Clayton KL, et al. 2021. Cell Host Microbe. 29(3):435-447.e9. PubMed
  39. Steindor M, et al. 2015. PLoS One. 10:119737. PubMed
  40. Todnem Sakkestad S, et al. 2019. Pathogens. 8. PubMed
  41. Kenswil KJG, et al. 2021. Exp Hematol. S0301-472X:00426. PubMed
  42. van Dongen JJM, et al. 2019. Front Immunol. 10:1271. PubMed
  43. Sananez I, et al. 2021. EBioMedicine. 72:103615. PubMed
  44. Ghassemi S, et al. 2022. Nat Biomed Eng. 6:118. PubMed
  45. Asashima H, et al. 2022. J Clin Invest. 132: . PubMed
  46. Gkika E, et al. 2023. NPJ Precis Oncol. 7:24. PubMed
  47. Tan X, et al. 2023. Adv Sci (Weinh). 10:e2206768. PubMed
  48. Boucher LE, et al. 2023. MAbs. 15:2195517. PubMed
  49. Apte SH, et al. 2020. Clin Transl Immunology. 9:e1209. PubMed
  50. Carre C, et al. 2021. iScience. 24:102970. PubMed
  51. Roberts A, et al. 2021. Sci Rep. 11:4030. PubMed
  52. Wang M, et al. 2022. Immun Inflamm Dis. 10:e626. PubMed
  53. Peng S et al. 2019. Cell Rep. 28(10):2728-2738 . PubMed
  54. Kasper M, et al. 2021. Elife. 10:. PubMed
  55. Wang S, et al. 2021. Exp Ther Med. 21:37. PubMed
  56. Vijayakumar B, et al. 2022. Immunity. . PubMed
  57. Vetsika EK, et al. 2021. Cancers (Basel). 13:. PubMed
  58. Guedan S, et al. 2018. JCI Insight. 3. PubMed
  59. Priyanto H, et al. 2021. J Clin Tuberc Other Mycobact Dis. 22:100214. PubMed
  60. Caduff N, et al. 2021. Cell Reports. 35(5):109056. PubMed
  61. Heger L, et al. 2018. Front Immunol. 9:744. PubMed
  62. Herrera FG, et al. 2019. Int J Radiat Oncol Biol Phys. 103:320. PubMed
  63. Breen EC, et al. 2022. iScience. 25:104488. PubMed
  64. Tu HA, et al. 2020. Cell Rep Med. 1:100155. PubMed
  65. Kalina T, et al. 2020. Front Immunol. 11:371. PubMed
  66. Idorn M, et al. 2018. Oncoimmunology. 7:e1412029. PubMed
  67. Khaitan A, et al. 2016. PLoS One. 11: 0161786. PubMed
  68. Lundtoft C, et al. 2017. PLoS Pathogens. 13(6):e1006425. PubMed
  69. De Domenico E, et al. 2020. STAR Protoc. 1:100233. PubMed
  70. Meckiff BJ, et al. 2020. Cell. 183(5):1340-1353.e16. PubMed
  71. Wing A, et al. 2018. Cancer Immunol Res. 6:605. PubMed
  72. Riese P, et al. 2022. Nat Commun. 13:6894. PubMed
  73. Janssen JJE, et al. 2022. Am J Physiol Endocrinol Metab. 322:E141. PubMed
  74. Menges D, et al. 2022. Nat Commun. 13:4855. PubMed
  75. Willmann K, et al. 2014. Nat Commun. 5:5360. PubMed
  76. Kaiser FMP, et al. 2021. J Allergy Clin Immunol. 147:391. PubMed
  77. Festag J, et al. 2020. Mol Ther Nucleic Acids. 1.330555556. PubMed
  78. Castellarin M, et al. 2020. JCI Insight. 5:00. PubMed
  79. Mackroth M, et al. 2016. PLoS Pathog. 12:e1005909. PubMed
  80. Diamantopoulos PT, et al. 2022. Cancers (Basel). 14:. PubMed
  81. Clayton KL, et al. 2021. Cell Host Microbe. 29(3):435-447.e9. PubMed
  82. Steindor M, et al. 2015. PLoS One. 10:119737. PubMed
  83. Todnem Sakkestad S, et al. 2019. Pathogens. 8. PubMed
  84. Kenswil KJG, et al. 2021. Exp Hematol. S0301-472X:00426. PubMed
  85. van Dongen JJM, et al. 2019. Front Immunol. 10:1271. PubMed
  86. Sananez I, et al. 2021. EBioMedicine. 72:103615. PubMed
RRID
AB_2561377 (BioLegend Cat. No. 317443)
AB_2561866 (BioLegend Cat. No. 317444)

Antigen Details

Structure
Ig superfamily, type I transmembrane glycoprotein, 55 kD
Distribution

T cell subset, majority of thymocytes, monocytes/macrophages

Function
MHC class II co-receptor, lymphocyte adhesion, thymic differentiation, HIV receptor
Ligand/Receptor
MHC class II molecules, HIV gp120, IL-16
Cell Type
Macrophages, Monocytes, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Center D, et al. 1996. Immunol. Today 17:476.
2. Gaubin M, et al. 1996. Eur. J. Clin. Chem. Clin. Biochem. 34:723.

Gene ID
920 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
Go To Top Version: 4    Revision Date: 07/13/2015

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account